126 related articles for article (PubMed ID: 2836572)
1. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma.
Madsen MT; Park CH; Thakur ML
J Nucl Med; 1988 Jun; 29(6):1038-44. PubMed ID: 2836572
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer.
Nakajo M; Kobayashi H; Shimabukuro K; Shirono K; Sakata H; Taguchi M; Uchiyama N; Sonoda T; Shinohara S
J Nucl Med; 1988 Jun; 29(6):1066-77. PubMed ID: 2836573
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.
Leichner PK; Klein JL; Siegelman SS; Ettinger DS; Order SE
Cancer Treat Rep; 1983; 67(7-8):647-58. PubMed ID: 6307515
[TBL] [Abstract][Full Text] [Related]
4. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma.
Leung WT; Lau WY; Ho S; Chan M; Leung N; Lin J; Ho KC; Metreweli C; Johnson PJ; Li AK
J Nucl Med; 1994 Aug; 35(8):1313-8. PubMed ID: 7519259
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study.
Park CH; Suh JH; Yoo HS; Lee JT; Kim DI
Clin Nucl Med; 1986 Jul; 11(7):514-7. PubMed ID: 3015472
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
7. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.
Chen ZN; Mi L; Xu J; Song F; Zhang Q; Zhang Z; Xing JL; Bian HJ; Jiang JL; Wang XH; Shang P; Qian AR; Zhang SH; Li L; Li Y; Feng Q; Yu XL; Feng Y; Yang XM; Tian R; Wu ZB; Leng N; Mo TS; Kuang AR; Tan TZ; Li YC; Liang DR; Lu WS; Miao J; Xu GH; Zhang ZH; Nan KJ; Han J; Liu QG; Zhang HX; Zhu P
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):435-44. PubMed ID: 16690431
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
[TBL] [Abstract][Full Text] [Related]
9. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
[TBL] [Abstract][Full Text] [Related]
10. Iodine-131-Lipiodol for hepatocellular carcinoma: the benefits of targeting.
Novell JR; Hilson AJ
J Nucl Med; 1994 Aug; 35(8):1318-20. PubMed ID: 8046486
[No Abstract] [Full Text] [Related]
11. [Intra-arterial injection of an oily antineoplastic agent in hepatic cancer].
Konno T; Tashiro S; Maeda H; Iwai K; Ogata K; Mochinaga M; Uemura K; Ishimaru S; Miyauchi Y; Yokoyama I
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):351-7. PubMed ID: 6309086
[TBL] [Abstract][Full Text] [Related]
12. [Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma].
Lu W; Li X; Wang C; Liu W; Jiao H; Mo T; Chen Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):689-91. PubMed ID: 14716878
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatocellular carcinoma (HCC) with radiolabeled Lipiodol: a preliminary report.
Park CH; Suh JH; Yoo HS; Lee JT; Kim DI; Kim BS
Nucl Med Commun; 1987 Dec; 8(12):1075-87. PubMed ID: 2835716
[TBL] [Abstract][Full Text] [Related]
14. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
Rhee TK; Omary RA; Gates V; Mounajjed T; Larson AC; Barakat O; Sato KT; Mulcahy M; Gordon S; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2005 Aug; 16(8):1085-91. PubMed ID: 16105920
[TBL] [Abstract][Full Text] [Related]
15. Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma.
Wang SJ; Lin WY; Lui WY; Chen MN; Tsai ZT; Ting G
J Nucl Med; 1996 Feb; 37(2):332-5. PubMed ID: 8667072
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
17. Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?
Bacher K; Brans B; Monsieurs M; De Winter F; Dierckx RA; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1311-6. PubMed ID: 12271412
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
Dancey JE; Shepherd FA; Paul K; Sniderman KW; Houle S; Gabrys J; Hendler AL; Goin JE
J Nucl Med; 2000 Oct; 41(10):1673-81. PubMed ID: 11037997
[TBL] [Abstract][Full Text] [Related]
19. Internal radiation by 131-iodine lipiodol in unresectable hepatocellular carcinoma.
Tabone M; Carbonatto P; Calvo A; Pellerito R; Stasi M; Daperno M; Rocca R
Dig Liver Dis; 2013 Nov; 45(11):962-3. PubMed ID: 23587497
[No Abstract] [Full Text] [Related]
20. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study.
Bernal P; Raoul JL; Vidmar G; Sereegotov E; Sundram FX; Kumar A; Jeong JM; Pusuwan P; Divgi C; Zanzonico P; Stare J; Buscombe J; Minh CT; Saw MM; Chen S; Ogbac R; Padhy AK
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1448-55. PubMed ID: 17692473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
